Celularity Inc. Gain (Loss) on Extinguishment of Debt
Celularity Inc. (CELU) reported Gain (Loss) on Extinguishment of Debt of -$6.36 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-04-30.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:GainsLossesOnExtinguishmentOfDebt · last filed 2026-04-30
- Celularity Inc. gain (loss) on extinguishment of debt for the quarter ending 2025-12-31 was $0.00.
- Celularity Inc. gain (loss) on extinguishment of debt for the quarter ending 2025-09-30 was -$620.00K.
- Celularity Inc. gain (loss) on extinguishment of debt for the quarter ending 2025-06-30 was $0.00.
- Celularity Inc. gain (loss) on extinguishment of debt for the quarter ending 2025-03-31 was -$5.74M.
- Celularity Inc. gain (loss) on extinguishment of debt for fiscal 2025 was -$6.36M.
- Celularity Inc. gain (loss) on extinguishment of debt for fiscal 2024 was -$3.91M.
| Period end | Gain (Loss) on Extinguishment of Debt | Gain (Loss) on Extinguishment of Debt 3 month | Gain (Loss) on Extinguishment of Debt 6 month | Gain (Loss) on Extinguishment of Debt 9 month | Gain (Loss) on Extinguishment of Debt 12 month |
|---|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-30 | -$620.00K derived: sum of 2 quarters · filed 2026-04-30 | -$620.00K derived: sum of 3 quarters · filed 2026-04-30 | -$6.36M 10-K · filed 2026-04-30 | |
| 2025-09-30 | -$620.00K 10-Q · filed 2025-11-14 | -$620.00K derived: sum of 2 quarters · filed 2025-11-14 | -$6.36M 10-Q · filed 2025-11-14 | -$6.36M derived: sum of 4 quarters · filed 2026-04-30 | |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-29 | -$5.74M 10-Q · filed 2025-08-29 | -$5.74M derived: sum of 3 quarters · filed 2026-04-30 | -$5.74M derived: sum of 4 quarters · filed 2026-04-30 | |
| 2025-03-31 | -$5.74M 10-Q · filed 2025-08-29 | -$5.74M derived: sum of 2 quarters · filed 2026-04-30 | -$5.74M derived: sum of 3 quarters · filed 2026-04-30 | -$5.74M derived: sum of 4 quarters · filed 2026-04-30 | |
| 2025-02-12 | $5.74M 10-Q · filed 2025-08-29 | ||||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-30 | $0.00 derived: sum of 2 quarters · filed 2026-04-30 | $0.00 derived: sum of 3 quarters · filed 2026-04-30 | -$3.91M 10-K · filed 2026-04-30 | |
| 2024-09-30 | $0.00 10-Q · filed 2024-12-06 | $0.00 derived: sum of 2 quarters · filed 2024-12-06 | -$3.91M 10-Q · filed 2025-11-14 | ||
| 2024-06-30 | $0.00 10-Q · filed 2024-11-07 | -$3.91M 10-Q · filed 2025-08-29 | |||
| 2024-03-31 | -$3.91M 10-Q · filed 2025-08-29 | ||||
| 2023-09-30 | $0.00 10-Q · filed 2024-12-06 | $0.00 derived: sum of 2 quarters · filed 2024-12-06 | $0.00 10-Q · filed 2024-12-06 | ||
| 2023-06-30 | $0.00 10-Q · filed 2024-11-07 | $0.00 10-Q · filed 2024-11-07 | |||
| 2023-03-31 | $0.00 10-Q · filed 2024-10-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 |